Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Manuela Rabaglio-Poretti"'
Autor:
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel Vander Meer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Metformin may exert anticancer effects through indirect (mediated by metabolic changes) or direct mechanisms. The goal was to examine metformin impact on metabolic factors in non-diabetic subjects and determine whether this impact varies by
Externí odkaz:
https://doaj.org/article/ed8c22cdd63b4d8ab3a69bbf18ba9909
Autor:
Pamela J. Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A Ligibel, Dawn L Hershman, Ingrid A Mayer, Timothy J Hobday, Judith M Bliss, Priya Rastogi, Manuela Rabaglio-Poretti, Som D. Mukherjee, Robert R Mackey, Vandana G Abramson, Conrad Oja, Robert Wesolowski, Alastair M Thompson, Daniel W Rea, Paul M Stos, Lois E Shepherd, Vuk Stambolic, Wendy R Parulekar
Publikováno v:
Cancer Research. 82:GS1-08
Background: MET has been associated with beneficial anti-cancer effects in epidemiologic and preclinical research. It may act indirectly by reversing obesity associated physiologic changes or directly via mitochondrial mediated effects on LKB1/AMPK/m
Autor:
Daniel Rea, Marguerite Ennis, Vuk Stambolic, Timothy J. Hobday, Ingrid A. Mayer, Manuela Rabaglio-Poretti, Julie Lemieux, Anagha Gurjal, Bingshu E. Chen, Rachel Vander Meer, Andrea Molckovsky, Dawn L. Hershman, Karen A. Gelmon, Timothy J. Whelan, Margot J. Burnell, Priya Rastogi, Jennifer A. Ligibel, Ryan J. O. Dowling, Alastair M. Thompson, Pamela J. Goodwin, Wendy R. Parulekar, Lois E. Shepherd
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
Metformin may exert anticancer effects through indirect (mediated by metabolic changes) or direct mechanisms. The goal was to examine metformin impact on metabolic factors in non-diabetic subjects and determine whether this impact varies by baseline
Autor:
Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Manuela Rabaglio-Poretti, Som D. Mukherjee, John R. Mackey, Vandana G. Abramson, Conrad Oja, Robert Wesolowski, Alastair M. Thompson, Daniel W. Rea, Paul M. Stos, Lois E. Shepherd, Vuk Stambolic, Wendy R. Parulekar
Publikováno v:
JAMA. 327(20)
Importance Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. Objective To determine whether the administration
Autor:
Priya Rastogi, Pamela J. Goodwin, Daniel Rea, Ryan J. O. Dowling, Wendy R. Parulekar, Alastair M. Thompson, Vuk Stambolic, Karen A. Gelmon, Marguerite Ennis, Manuela Rabaglio-Poretti, Timothy J. Hobday, Lois E. Shepherd, Ingrid A. Mayer, Jennifer A. Ligibel, Bingshu E. Chen, Dawn L. Hershman, Timothy J. Whelan, Julie Lemieux
Publikováno v:
JNCI Cancer Spectrum
Background Circulating levels of cancer antigen (CA) 15–3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of metformin (vs placebo) on CA 15–3 in partic
Autor:
Johan Vansteenkiste, Amanda Tufman, M. Guckenberger, Dirk De Ruysscher, Miklos Pless, N. Andratschke, Maarten Lambrecht, Alex Martinez-Marti, Antonio Irigoyen, M. Kassapian, A.-C. Piguet, H. Roschitzki-Voser, Enriqueta Felip, Manuela Rabaglio-Poretti, Rolf A. Stahel, Urania Dafni, Claus Belka, H. Vees, Solange Peters, E. Nadal, A. Becker
Publikováno v:
Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Tufman, A, Lambrecht, M, Andratschke, N, Piguet, A C, Kassapian, M, Roschitzki-Voser, H, Rabaglio-Poretti, M, Stahel, R A, Vansteenkiste, J & De Ruysscher, D 2019, ' Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial ', Lung Cancer, vol. 133, pp. 83-87 . https://doi.org/10.1016/j.lungcan.2019.05.001
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in preclinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material
Autor:
Barbara Ruepp, Rupert Bartsch, Andrea Gombos, Frances M. Boyle, Giuseppe Viale, Anita Hiltbrunner, Thomas Bachelot, Martine Piccart-Gebhart, Caitlin Mahoney, Debora Fumagalli, Rina Hui, Theodora Goulioti, Fabrice Andre, Marco Colleoni, Carmen Comune, Magdelena Weber, Michelle Jenkins, Stefan Aebi, Stefania Andrighetto, Stamatina Fournarakou, Meredith M. Regan, Colleen King, Angelo Di Leo, Alan S. Coates, Rita Hui, Aron Goldhirsch, Mario Campone, Per Karlsson, Rolf A. Stahel, Vassiliki Karantza, Hui Huang, Laura Biganzoli, Hervé Bonnefoi, Sabrina Ribeli-Hofmann, Roswitha Kammler, Magdalena Sánchez-Hohl, Karolyn Scott, Patrick Schneier, Giuseppe Curigliano, Ingrid Kössler, Sherene Loi, Heather Findlay, Richard D. Gelber, Holly Shaw, Guy Jerusalem, Susan Fischer, Anita Giobbie-Hurder, Daniela Celotto, Manuela Rabaglio-Poretti, Rita Pfister, Michela Frapolli, Monica Greco, Adriana Gasca, Mark J. Smyth, Jaime A. Mejia, Karen N. Price, Heidi Roschitzki, Rudolf Maibach
Publikováno v:
The Lancet Oncology. 20:371-382
Summary Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tum
Autor:
Rudolf Maibach, Roswitha Kammler, A. Di Leo, A. S. Coates, Kathryn P. Gray, L. Gianni, Harriet Johansson, Silvia Dellapasqua, G. Viale, Meredith M. Regan, R. D. Gelber, A. Goldhirsch, Manuela Rabaglio-Poretti, Claudio Zamagni, Elisabetta Munzone, M.A. Colleoni
Publikováno v:
Cancer Research. 78:P1-10
Background: Neoadjuvant endocrine therapy (NET) with gonadotropin-releasing hormone (GnRH) agonist and aromatase inhibitors is effective in selected premenopausal patients (pts). Degarelix, an antagonist of GnRH, has immediate onset of action through
Autor:
R Hui, A Di Leo, R Bartsch, Sherene Loi, M Campone, Meredith M. Regan, Manuela Rabaglio-Poretti, MJ Smyth, Rudolf Maibach, T Bachelot, F Andre, H Bonnefoi, Roswitha Kammler, G. Jerusalem, G Curigliano, A Gombos, G Viale, A Giobbe-Hurder, L Biganzoli, Marco Colleoni
Publikováno v:
Cancer Research. 78:GS2-06
Background Preclinical and clinical data suggest that HER2-positive (HER2+) breast cancer (BC) will be amendable to immunotherapeutic approaches. We evaluated pembrolizumab with trastuzumab in patients (pts) with trastuzumab-resistant HER2+, PD-L1 po
Autor:
Marco Colleoni, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Erika Hitre, Marie-Pascale Graas, Edda Simoncini, Claus Kamby, Alastair Thompson, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Christian Marth, Bettina Müller, Seamus O'Reilly, Vincenzo Di Lauro, Andrea Gombos, Thomas Ruhstaller, Harold Burstein, Karin Ribi, Jürg Bernhard, Giuseppe Viale, Rudolf Maibach, Manuela Rabaglio-Poretti, Richard D Gelber, Alan S Coates, Angelo Di Leo, Meredith M Regan, Aron Goldhirsch, An Vandebroek, Martine Berliere, Carine Mitine, Peter Vuylsteke, Marleen Borms, Randal D'Hondt, Philippe Glorieux, Jeroen Mebis, Didier Verhoeven, Michael Coibion, Frederic Forget, Lionel Duck, Wim Wyendaele, Annelore Barbeaux, Jean-Paul Salmon, Patrick Berteloot, Joanna Vermeij, Vincent Richard, Saverio Cinieri, Lorenzo Gianni, Mario Clerico, Graziella Pinotti, Antonio Bernardo, Leo Biganzoli, Alessandra Gennari, Claudio Graiff, Dino Amadori, Rodolfo Passalacqua, John Forbes, Prudence Francis, Serene Foo, Frances Boyle, Andrew Redfern, Andre van der Westhuizen, Craig Lewis, Sharad Sharma, Philip Beale, Ian Byard, Stephen Begbie, Frank Sardelic, Ehtesham Abdi, David Clark, Aaron Chindewere, Stephen Della-Fiorentina, Ray Asghari, Mohammed Islam, Lee Na Teo, Shane White, Linda Gilbert, Katherine Gardner, Catarina Uhlmann, Daniel Rauch, Meinrad Mannhart, Katharina Buser, Konstantin Dedes, Andreas Mueller, Christoph Rageth, Stephanie Von Orelli, Hans Joerg Senn, Olivia Pagani, Augusto Pedrazzini, Christoph Rochlitz, Alexandre Bodmer, Sandro Anchisi, Khalil Zaman, Roger von Moos, Daniel Betticher, Elena Kralidas, Razven Popescu, Mathias Fehr, Per Nyman, Anja Jungquist, Chaido Chamalidou, Theodoros Foukakis, Charlotta Dabrosin, Antonis Valachis, Istvan Lang, Zsuzsanna Kahan, Javier Retamales, Ulloa Roberto Torres, Marcela Fritis, Sebastian Sole, Soledad Torres, Jaime Letzkus, Paula Escobar, Ines Vigneaux, Jorge Arancibia, Juana Bernardita Cardemil, Patricio Huidobro, Henry Gomez, Julie Wetter, Daniel Vorobiof, Gary McMichael, Justus Apffelstaedt, Igor Vorotnikov, Joel Schwartz, Thomas Openshaw, Herve Bonnefoi, Jean-Philippe Jacquin, Natalie Bonichon-Lamichhane, Simona Borstner, Ashwini Budrukkar, Marianne Ewertz, Oscar Zambrano Quispe, Peter Michael Vestlev, Hella Danø, Ditte Nielsen, Erik Jakobsen, Inger Hoejris, Jurij Antonovic Bogovic, Britta Bjerregaard Jensen, Knud Aage Møller, Eric Lars Stenbygaard, Ravi Sharma, Carolyn Bedi, Maria Bews-Hair, Glyn Neades, Mike McKirdy, Matthew Barber, Abdulla Alhasso, Diana Ritchie, Judith Fraser, Lucy Scott, Frances Yuille, Alison Lannigan, Dermot Murphy, Mike Shere, Christian Jackisch, Oliver Tomé, Susanne Steer, Doris Augustin, Kristina Lübbe, Heike Köcker-Korus, Jörg-Uwe Deuker, Andrea Stefek, Marianne Just, Uwe Rhein, Christina Bechtner, Dirk-Toralf Baerens, Iris Schrader, Eva-Maria Grischke, Ralf Lorenz, Wolfgang Dietz, Jörg Thomalla, Jörg Schilling, Andreas Rempen, Heiko Graf, Gabriele Doering, Steffi Busch, Georg Heinrich, Hans Tesch, Christoph Uleer, Petra Krabisch, Siegfried Rösel, Christian Kurbacher, Horst Ostertag, Klaus-M Josten, Carsten Hielscher, Isolde Gröll, Ute Marie Mattner, Anita Prechtl, Tilmann Lantzsch, Eva Ciruelos, Isabel Garau, Meritxell Bellet, Miguel Angel Climent, Rafael López, Juan Antonio Virizuela, Begoña Bermejo, Noelia Martinez Janez, Kepa Amillano, Raúl Márquez, Joan Dorca, Maria Jose Godes, Santiago Gonzalez, Shinji Ohno, Tomoyuki Aruga, Daisuke Yotsumoto, Yutaka Yamamoto, Tomohiko Aihara, Takashi Morimoto, Hiroko Bando, Norikazu Masuda, Masakazu Toi, Kenjiro Aogi, Nobuaki Sato, Morihito Okada, Masato Takahashi, Eriko Tokunaga, Hiroji Iwata, Takashi Fujita, Michael Fridrik, Gunda Pristauz, Claudia Hackl, Christian Singer, Victor Wette, Michael Gnant, Josef Thaler, Richard Greil, Burghard Abendstein, Dietmar Heck, Diether Manfreda, Paul Sevelda, Irene Thiel, Frank Tuttlies, Herbert Stöger, Walter Neunteufel, John Crown, John Kennedy, Arnold Hill, John McCaffrey, Conleth Murphy, Linda Coate, Maccon Keane, Michael Martin, Miriam O'Connor, Karen Duffy, Barbara Ruepp, Martine Piccart, Dimitrios Zardavas
Publikováno v:
The Lancet Oncology. 19:127-138
In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that extended intermittent use of adjuvant letrozole would improve breast cancer out